HOME

TheInfoList



OR:

The Alzheimer's Drug Discovery Foundation (ADDF) is a
nonprofit organization A nonprofit organization (NPO), also known as a nonbusiness entity, nonprofit institution, not-for-profit organization, or simply a nonprofit, is a non-governmental (private) legal entity organized and operated for a collective, public, or so ...
founded in 1998 by co-chairmen Leonard A. Lauder and Ronald S. Lauder of the Estée Lauder Companies cosmetics family and led by Howard Fillit, a geriatrician and neuroscientist. The ADDF provides funding to scientists who are conducting promising, innovative
Alzheimer's disease Alzheimer's disease (AD) is a neurodegenerative disease and the cause of 60–70% of cases of dementia. The most common early symptom is difficulty in remembering recent events. As the disease advances, symptoms can include problems wit ...
drug research worldwide. The ADDF funds early-stage research and early-phase
clinical trials Clinical trials are prospective biomedical or behavioral research studies on human subject research, human participants designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel v ...
that might otherwise go unfunded. By supporting research projects around the world, it seeks to increase the chances of finding treatments for Alzheimer's disease, related
dementia Dementia is a syndrome associated with many neurodegenerative diseases, characterized by a general decline in cognitive abilities that affects a person's ability to perform activities of daily living, everyday activities. This typically invo ...
s and cognitive aging. The ADDF has invested nearly $65 million to fund some 450 Alzheimer's
drug discovery In the fields of medicine, biotechnology, and pharmacology, drug discovery is the process by which new candidate medications are discovered. Historically, drugs were discovered by identifying the active ingredient from traditional remedies or ...
programs and clinical trials in academic centers and
biotechnology Biotechnology is a multidisciplinary field that involves the integration of natural sciences and Engineering Science, engineering sciences in order to achieve the application of organisms and parts thereof for products and services. Specialists ...
companies in 18 countries.


Funding model

The ADDF is a biomedical
venture philanthropy Venture philanthropy is a type of impact investment that takes concepts and techniques from venture capital finance and business management and applies them to achieving philanthropic goals. The term was first used in 1969 by John D. Rockefeller ...
. Many of its grants are structured as investments, providing a return that is reinvested in new drug research. After initial ADDF funding, grantees have received commitments of over $2 billion in follow-on funding from government, pharmaceutical companies and venture capital firms to further advance drug research.


ADDF programs

Through its programs, the ADDF has invested close to $65 million to fund nearly 450 Alzheimer's
drug discovery In the fields of medicine, biotechnology, and pharmacology, drug discovery is the process by which new candidate medications are discovered. Historically, drugs were discovered by identifying the active ingredient from traditional remedies or ...
programs and clinical trials in academic centers and
biotechnology Biotechnology is a multidisciplinary field that involves the integration of natural sciences and Engineering Science, engineering sciences in order to achieve the application of organisms and parts thereof for products and services. Specialists ...
companies in 18 countries. From 2000 to 2004, the ADDF provided seed funding for Amyvid, the first FDA-approved diagnostic test for Alzheimer's disease. The ADDF also funded PrecivityAD, the first blood test to help diagnose Alzheimer's disease.


Partnership Programs

The ADDF partners with family foundations, government, non-profit organization, the pharmaceutical industry and corporate organizations to leverage collective funding power.


Scientific Conferences

The ADDF hosts, sponsors and attends a number of scientific conferences, including the International Conference on Alzheimer's Drug Discovery and the Drug Discovery for Neurodegeneration Conference. The ADDF also organizes advisory panels focused on key issues surrounding drug discovery and development for Alzheimer's.


Cognitive Vitality

The ADDF's microsite, Cognitive Vitality, provide evidence-based answers to pressing questions about healthy brain aging. Resources include: * Expert ratings of scientific evidence for and against suggested cognitive vitality strategies including: health management and drugs; nutrition and supplements; and environmental and physical considerations * Practical information on safety, efficacy and drug dosage * Digestible translations of scientific findings


Awards


Melvin R. Goodes Prize for Excellence in Drug Development

The Melvin R. Goodes Prize for Excellence in Drug Development, also known simply as the Goodes Prize, was first awarded in 2015. It is awarded annually by the Alzheimer’s Drug Discovery Foundation for innovations in research that have made a significant and lasting impact in the Alzheimer’s field. Recipients receive an engraved medal and a monetary award of $150,000 to support their continued research in Alzheimer’s therapeutics, biomarkers, or prevention programs. The award is named in honor of Melvin R. Goodes, a former Chairman and Chief Executive of Warner-Lambert. Goodes established the prize with his wife, Nancy, and in partnership with the Alzheimer’s Drug Discovery Foundation after his own diagnosis with Alzheimer’s disease in 2009.


Goodes prize recipients


Events

Every year, the ADDF hosts a series of events to raise awareness and funds to support Alzheimer's research and drug development. They include: *The Hope on the Horizon Palm Beach event, which honors an Alzheimer’s advocate who has helped to advance the ADDF’s mission. *Tomorrow’s Breakthroughs Today, a Palm Beach-based scientific symposium series that highlights three scientists sharing updates on the latest Alzheimer’s research advances each year. *The Great Ladies Luncheon and Fashion Show, an annual spring runway show and lunch recognizing female advocates in Alzheimer's. Previous events have included designs and special appearances by Erdem, Jason Wu and
Carolina Herrera Carolina Herrera (born María Carolina Josefina Pacanins y Niño, 8 January 1939) is a Venezuelan Americans, Venezuelan American fashion designer. Known for her personal style, she founded her namesake brand in 1980. Herrera has designed for va ...
. *The Connoisseur's Dinner, an evening of art and wine celebrating scientific progress in Alzheimer's research. *The Fall Symposium and Luncheon, a luncheon and learning event featuring a keynote speech or panel highlighting progress in cognitive decline research and drug development.


References

{{Reflist


External links


Official Website
Medical and health foundations based in the United States Social finance Medical and health organizations based in New York (state)